{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:34:35Z","timestamp":1747208075499,"version":"3.40.5"},"reference-count":43,"publisher":"Informa UK Limited","issue":"37","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.2217\/fon-2022-0478","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T10:45:13Z","timestamp":1671101113000},"page":"4111-4118","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Borderline Indications for Ovarian Suppression: Addressing Uncertainties with Patients"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-5261","authenticated-orcid":false,"given":"Max","family":"S Mano","sequence":"first","affiliation":[{"name":"Centro Paulista de Oncologia,Grupo Oncocl\u00ednicas,\rS\u00e3o Paulo \u2013 SP,\r04538-132,\rBrazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412379"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803164"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00126"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8675"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00049-2"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.08.002"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70869-5"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182864350"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0946"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01967"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806285"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.551"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2011.05.002"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds536"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00066"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03398"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01204"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017"},{"issue":"4","key":"e_1_3_2_22_1","article-title":"Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis [abstract].","volume":"80","author":"Mano MS","year":"2020","unstructured":"Mano MS , LoiblS, MamounasEPet al. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis [abstract]. Proceedings of the 2019 San Antonio Breast Cancer Symposium; Cancer Res. 80(Suppl. 4), Abstract nr P3-14-01 (2020).","journal-title":"Proceedings of the 2019 San Antonio Breast Cancer Symposium;"},{"issue":"4","key":"e_1_3_2_23_1","article-title":"Breast cancer recurrence and predictors for recurrence despite pathologic complete response following neoadjuvant chemotherapy [abstract].","volume":"79","author":"Borremans K","year":"2019","unstructured":"Borremans K , BertelootP, Van NieuwenhuysenEet al. Breast cancer recurrence and predictors for recurrence despite pathologic complete response following neoadjuvant chemotherapy [abstract]. Proceedings of the 2018 San Antonio Breast Cancer Symposium; AACR; Cancer Res. 79(Suppl. 4), Abstract nr P1-15-04 (2019).","journal-title":"Proceedings of the 2018 San Antonio Breast Cancer Symposium; AACR;"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz097"},{"issue":"4","key":"e_1_3_2_25_1","article-title":"Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis [abstract].","volume":"80","author":"Swain SM","year":"2020","unstructured":"Swain SM , MacharrlaH, CortesJet al. Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis [abstract]. Proceedings of the 2019 San Antonio Breast Cancer Symposium; AACR; Cancer Res. 80(Suppl. 4), Abstract nr P1-18-01 (2020).","journal-title":"Proceedings of the 2019 San Antonio Breast Cancer Symposium; AACR;"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00163-7"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8595"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4964-y"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.04.020"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08039-7"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5600-x"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4273"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0111-0"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.506"},{"issue":"4","key":"e_1_3_2_35_1","article-title":"First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +\/- chemotherapy (CT) in patients (pts) with 1\u20133 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <25: SWOG S1007 (RxPonder) [abstract].","volume":"81","author":"Kalinsky K","year":"2021","unstructured":"Kalinsky K , BarlowWE, Meric-BernstamFet al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +\/- chemotherapy (CT) in patients (pts) with 1\u20133 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <25: SWOG S1007 (RxPonder) [abstract]. Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; AACR; Cancer Res. 81(Suppl. 4), Abstract nr GS3-00 (2021).","journal-title":"Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; AACR;"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0614-x"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Ellis MJ SumanVJ HoogJet al. Randomized phase II neoadjuvant comparison between letrozole anastrozole and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype \u2013 ACOSOG Z1031. 29(17) 2342\u20139 (2011).","DOI":"10.1200\/JCO.2010.31.6950"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds132"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.671"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01959"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu544"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33367"},{"issue":"4","key":"e_1_3_2_44_1","article-title":"Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women [abstract].","volume":"79","author":"Gray R","year":"2019","unstructured":"Gray R , Early Breast Cancer Trialists' Collaborative Group. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women [abstract].Proceedings of the 2018 San Antonio Breast Cancer Symposium; AACR;Cancer Res.79(Suppl. 4), Abstract nr GS3-03 (2019).","journal-title":"Proceedings of the 2018 San Antonio Breast Cancer Symposium; AACR;"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61963-1"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:33Z","timestamp":1719125193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":43,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.2217\/fon-2022-0478"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0478","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}